Clinical management of recurrent breast cancer: Development of multidrug resistance (MDR) and strategies to circumvent it

Seminars in Oncology

Volumn 32, Issue SUPPL. 7, 2005, Pages

  Hait, William N ^a   Yang, Jin Ming ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; CYCLOSPORIN A; DOXORUBICIN; FLUPENTIXOL; GLYCOPROTEIN P; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CARCINOMA; BRUSH BORDER; CANCER RECURRENCE; CAPILLARY ENDOTHELIUM; CHEMOSENSITIVITY; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG PENETRATION; DRUG SENSITIVITY; ENDOTHELIUM CELL; GASTROINTESTINAL TRACT; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; RNA INTERFERENCE;

ANTIGENS, CD147; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM RECURRENCE, LOCAL; P-GLYCOPROTEIN;

EID: 28944438547     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.008     Document Type: Article

References (34)

1. J.H. Gerlach, N. Kartner, D.R. Bell Multidrug resistance Cancer Surv 5 1986 25 46
2. B.J. Trock, F. Leonessa, R. Clarke Multidrug resistance in breast cancer A meta-analysis of MDR1/gp170 expression and its possible functional significance J Natl Cancer Inst 89 1997 917 931
3. M.M. Gottesman, T. Fojo, S.E. Bates Multidrug resistance in cancer Role of ATP-dependent transporters Nat Rev Cancer 2 2002 48 58
4. G.D. Leonard, T. Fojo, S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
5. J.M. Ford, J.M. Yang, W.N. Hait P-glycoprotein-mediated multidrug resistance Experimental and clinical strategies for its reversal Cancer Treat Res 87 1996 3 38
6. S.K. Chambers, W.N. Hait, B.M. Kacinski Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues Cancer Res 49 1989 6275 6279
7. J.M. Ford, J.M. Yang, W.N. Hait Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice Cancer Res 51 1991 67 72
8. W.N. Hait, J.F. Gesmonde, J.R. Murren Terfenadine (Seldane) A new drug for restoring sensitivity to multidrug resistant cancer cells Biochem Pharmacol 45 1993 401 406
9. W.N. Hait, S. Choudhury, S. Srimatkandada Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents J Clin Invest 91 1993 2207 2215
10. J.M. Yang, S. Goldenberg, M.M. Gottesman Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists Cancer Res 54 1994 730 737
11. D.L. Cooper, I.M. Braverman, A.H. Sarris Cyclosporine treatment of refractory T-cell lymphomas Cancer 71 1993 2335 2341
12. J.R. Murren, H.J. Durivage, A.C. Buzaid Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer Cancer Chemother Pharmacol 38 1996 65 70
13. A.W. Tolcher, K.H. Cowan, D. Solomon Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer J Clin Oncol 14 1996 1173 1184
14. J.M. Yang, G.Y. Yang, D.J. Medina Treatment of multidrug resistant (MDR1) murine leukemia with P-glycoprotein substrates accelerates the course of the disease Biochem Biophys Res Commun 266 1999 167 173
15. J.M. Yang, A. Vassil, W.N. Hait Involvement of phosphatidylinositol-3- kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells Biochem Pharmacol 63 2002 959 966
16. T. Muramatsu, T. Miyauchi Basigin (CD147) A multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion Histol Histopathol 18 2003 981 987
17. J.M. Yang, Z. Xu, H. Wu Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells Mol Cancer Res 1 2003 420 427
18. C. Cordon-Cardo, J.P. O'Brien, D. Casals Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci U S A 86 1989 695 698
19. A. Rice, M.L. Michaelis, G. Georg Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors J Mol Neurosci 20 2003 339 343
20. S. Fellner, B. Bauer, D.S. Miller Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo J Clin Invest 110 2002 1309 1318
21. L.J. Goldstein, A.T. Fojo, K. Ueda Expression of the multidrug resistance, MDR1, gene in neuroblastomas J Clin Oncol 8 1990 128 136
22. M. Li, R. Hurren, R.L. Zastawny Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium Br J Cancer 80 1999 1123 1131
23. C. Zimmermann, H. Gutmann, P. Hruz Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract Drug Metab Dispos 33 2005 219 224
24. A. Sparreboom, J. van Asperen, U. Mayer Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc Natl Acad Sci U S A 94 1997 2031 2035
25. T. Fojo, S. Bates Strategies for reversing drug resistance Oncogene 22 2003 7512 7523
26. J.M. Yang, A.D. Vassil, W.N. Hait Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway Mol Pharmacol 60 2001 674 680
27. H. Wu, W.N. Hait, J.M. Yang Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells Cancer Res 63 2003 1515 1519
28. H. Kang, M.H. Fisher, D. Xu Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides Nucleic Acids Res 32 2004 4411 4419
29. Z. Zhang, J.Y. Wu, W.N. Hait Regulation of the stability of P-glycoprotein by ubiquitination Mol Pharmacol 66 2004 395 403
30. A.M. Burger, A.K. Seth The ubiquitin-mediated protein degradation pathway in cancer Therapeutic implications Eur J Cancer 40 2004 2217 2229
31. S.V. Rajkumar, P.G. Richardson, T. Hideshima Proteasome inhibition as a novel therapeutic target in human cancer J Clin Oncol 23 2005 630 639
32. S. Goodin, M.P. Kane, E.H. Rubin Epothilones Mechanism of action and biologic activity J Clin Oncol 22 2004 2015 2025
33. K.H. Altmann, M. Wartmann, T. O'Reilly Epothilones and related structures - A new class of microtubule inhibitors with potent in vivo antitumor activity Biochim Biophys Acta 1470 2000 M79 M91
34. S.E. Bates, S. Bakke, M. Kang A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma Clin Cancer Res 10 2004 4724 4733